Strategic partnerships OBD has a track record of 40+ partnerships with pharma and leading institutions, including Pfizer, Roche, Genentech, Biogen, and Mayo Clinic. This indicates a strong partnership-led sales approach and opportunities to expand collaborations with large pharma, contract research organizations, and academic centers for wider adoption of EpiSwitch tests.

Clinical adoption hubs They maintain a global footprint with a 24,000 sq ft HQ in Oxford, an ISO-certified laboratory in Penang, and a commercial team in Gaithersburg, MD. This setup supports multi-region deployment of tests and enables rapid access for US-based payer discussions, clinical labs, and hospital systems.

Product expansion Recent launches include EpiSwitch Prostate Screening and the CiRT Checkpoint inhibitor Response Test, suggesting ongoing product diversification. Potential sales angles include hospital-based screening programs, oncology clinics, and immunotherapy guidance services across geographies.

Cloud analytics A collaboration with Google Cloud to accelerate cloud-based analytical framework signals a push toward scalable data analytics and decision-support for precision medicine. This opens opportunities to offer data services, cloud-enabled dashboards, and value-add analytics packages to pharma, labs, and health systems.

Clinical access network OBD collaborates with CLIA-certified commercial labs to deliver tests through physician pathways. This established distribution and lab network can be leveraged to expand payer-ready test offerings, accelerate reimbursement discussions, and scale adoption in diverse clinical settings.